For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$104.82
Thesis
Lantheus is a commercial-stage leader in radiopharmaceutical diagnostics with a market-leading prostate cancer PET imaging agent. Cash flow from established products funds expansion into therapeutic radioligands.
Catalysts
- Pylarify volume growth and competitive defense
- Therapeutic radioligand pipeline build-out
- Business development in diagnostics and therapy